BLRX eyes 50-DMA breakout after cancer trial update

BioLineRx (BLRX) surged 10% premarket, targeting a break above its 50-DMA for the first time since March. The move follows dosing the first patient in a Phase 1 trial for brain cancer therapy GLIX1. Partnered with Hemispherian, the therapy showed strong preclinical data. Initial results are expected in H1 2027.